INTRODUCTION
rearrangements in infected cells (32, 41); whereas NS4B, along with NS2A, co-localizes with 61 replication complexes (28, 32) . NS5 functions as a methyltransferase (12, 40, 51) and an RNA- shown to inhibit flaviviruses, primarily through depletion of intracellular GTP pool (22).
84
In this study, we report a novel inhibitor of host DHODH. The compound was identified 
MATERIALS AND METHODS

93
Viruses, compounds, and antibodies. We used the following viruses: WNV (strain 94 3356), YFV (17D vaccine strain), DENV-2 (strains New Guinea C and TSV01), Western equine 95 encephalitis virus (WEEV; strain Cova 746), and Vesicular stomatitis virus (VSV; New Jersey 96 serotype). The sources of these viruses were reported previously (50). Vero, A549, and Huh-7 97 cells were used for virus infection as specified in individual experiments. All compounds used in 98 this report were synthesized in-house and were dissolved in 90% DMSO for in vitro experiments.
99
DENV specific mouse monoclonal antibody 4G2 against envelope protein was prepared from 100 hybridoma cell line purchased from American Type Culture Collection (ATCC).
7
Replicon assay. Replicon assay was performed as described previously (35 insert. The RED device was incubated at ~37°C while shaking at 100 rpm for 4 hours.
176
Afterwards, an aliquot was removed from each chamber and equal amounts of fresh plasma and
177
PBS were added to respective incubated aliquots. The plasma/PBS mixtures were precipitated 178 using acetonitrile. After mixing and centrifugation, the supernatant was transferred to a clean 96-
179
well plate for LC/MS/MS analysis.
180
The in vivo efficacy of NITD-982 was evaluated in a dengue viremia model in mice (43). were monitored twice a day, and blood samples were collected on day 3 p. 
RESULTS
192
A cell-based cytopathic effect (CPE) inhibition assay. We developed a high- reduced viral E protein production in a dose-dependent manner, with an estimated EC 50 to be 2.4 212 nM (Fig. 1B) . Next, the antiviral activity of NITD-982 was further confirmed by a viral titer 213 reduction assay. As shown in Fig. 1C using an E.coli expression system (Fig. 4A) . A chromogen reduction assay was used to monitor 257 the activity of DHODH by measuring the reduction of 2,6 -dichlorophenolindophenol (DCIP),
258
which is stoichiometrically equivalent to the oxidation of dihydroorotate to orotate; the reaction 259 was quantified by a spectrophotometer at 610 nM wavelength (3, 10). As shown in Fig. 4B although the protein/compound stoichiometry was shifted to 2:1 (Fig. 4C) additive.
300
The WT sequence of DENV-1, -3, and -4 bears a Gln residue at position 802 of the NS5.
301
The fact that DENV-2 containing the E802Q substitution was resistant to NITD-982 suggests respectively (data not shown).
307
The requirement of Gln at amino acid 802 of NS5 for viral resistance to NITD-982 raised efficacy, we measured the uridine concentrations in plasma collected on day 3 post-infection.
334
The average plasma concentrations of uridine range from 6.6 to 8.2 µM in the compound-treated 335 mice (Fig. 7C ). Student's t test suggest that, compared with the vehicle-treated group, only the 336 30 mg/kg-treated group showed significantly lower uridine concentration in plasma (p < 0.05).
337
Collectively, the results suggest that the compound was not able to suppress the uridine 338 concentration to a level low enough to achieve in vivo efficacy. 
367
Cross resistance analysis showed that, besides the M260V mutation in envelope protein,
368
an E802Q substitution in the viral RdRp domain could also confer partial resistance to both
369
Brequinar and NITD-982 (Fig. 6A) . The E802Q mutation is located at the priming loop of the (Fig. 1C) . Pharmacokinetic analysis showed that the compound reached a C max of 528 nM 392 after dosing at 10 mg/kg in cotton rats (Fig. 7A) ; the C max of 528 nM was about 100-fold above 393 the EC 90 value. However, the compound did not achieve any in vivo efficacy, even when the uridine concentration in the compound-treated animal remained to be 6.6 to 8.2 µM (Fig. 7C) ; 399 uridine at these concentrations could reverse the compound-mediated antiviral activity in cell 400 culture (Fig. 5) 
